Tag: bone graft

  • Eggshell Against Synthetic Hydroxyapatite, in Actual Jaws

    Eggshell Against Synthetic Hydroxyapatite, in Actual Jaws

    The case for eggshell-derived hydroxyapatite is usually argued in a laboratory. It is cheaper. It valorises a waste stream. Its trace chemistry sits closer to biological apatite than a reagent-grade synthetic does.

    All of which is interesting, and none of which is the question a surgeon asks. The question a surgeon asks is whether bone comes back.

    Two grafts, one defect type

    In 2025, Changani, Managutti, Menat, Patel, Kattimani, Panchal and Girija published a study in the Journal of Oral Biology and Craniofacial Research comparing eggshell-derived hydroxyapatite against synthetic hydroxyapatite in the regeneration of maxillofacial defects.

    The eggshell material was made the way the current literature makes it: hen’s eggshells washed and calcined to calcium oxide, mixed with 0.5 M diammonium hydrogen phosphate at a Ca/P ratio of 1.67, then formed under microwave irradiation at 800 W. Before it went anywhere near a patient it took 25 kGy of gamma irradiation for sterilisation.

    That last detail is not incidental, and readers of this blog will recognise why. Sterilisation is a processing step that can change a calcium phosphate — so whatever was measured in this study was measured on post-irradiation material, which is the honest place to measure it.

    What the numbers said

    At six months and at one year, bone density in the eggshell arm ran ahead of the synthetic arm: 136.04 ± 15.56 against 115.58 ± 16.26, a difference the authors report as statistically significant.

    And yet their conclusion opens with equivalence: “Both EHA and SHA graft materials are equally efficient in early bone regeneration. The EHA showed promising results and enhanced bone regeneration with osteoconductivity.”

    Both halves of that sentence are doing work. Early on, the two materials behave the same. Later, they separate. A claim built on the first half is a claim about interchangeability; a claim built on the second is a claim about superiority at twelve months. They are not the same claim, and a specification sheet that quotes one while implying the other is overreaching.

    The part that does not travel

    Here is the limit worth stating plainly. This result belongs to that eggshell-derived material — that calcination, that Ca/P ratio, that microwave route, that gamma dose — and not to eggshell-derived hydroxyapatite as a category.

    The trace elements that make biogenic apatite interesting are inherited from the shell, and shells vary with flock, feed and region. The phase composition is decided by the synthesis route. The surface is decided by what sterilisation did to it. Change any of those and you have a material with the same name and a different biological argument.

    So the finding is genuinely good news for the category, and it is not transferable evidence for any particular drum of powder. What makes it transferable is a supplier who can show that their route, their ratio and their sterilisation are the same ones every time — which is, once again, the whole question.

    Sources

    Changani, Managutti, Menat, Patel, Kattimani, Panchal, Girija. “Evaluating the efficacy of eggshell-derived hydroxyapatite (EHA) and synthetic hydroxyapatite (SHA) in bone regeneration of maxillofacial defects.” Journal of Oral Biology and Craniofacial Research, 2025 (open access) — pmc.ncbi.nlm.nih.gov/articles/PMC12804149.

  • Hydroxyapatite in Bone Graft Substitutes: A Procurement Guide to Granules, Blocks, and Putties

    Hydroxyapatite in Bone Graft Substitutes: A Procurement Guide to Granules, Blocks, and Putties

    Hydroxyapatite in Bone Graft Substitutes: A Procurement Guide to Granules, Blocks, and Putties

    Hydroxyapatite’s compositional similarity to the mineral phase of bone makes it a long-established synthetic bone graft material. For procurement and biomaterials teams, the practical questions are less about whether to use it and more about which physical format, what porosity, and which specifications matter for a given clinical or research application. This is a buyer-oriented overview, not clinical guidance.

    Why Hydroxyapatite for Bone

    Bone mineral is essentially a carbonated apatite, so synthetic hydroxyapatite is inherently osteoconductive, it provides a scaffold onto which the body’s own bone-forming cells can migrate and lay down new tissue. It is biocompatible and, depending on its form, can remain as a long-term scaffold or be gradually remodelled. The exact behaviour is governed by chemistry, crystallinity, and architecture, which is where format and specification come in.

    The Three Common Formats

    Granules are loose particles, typically supplied in defined size ranges. They conform to irregular defect shapes, are easy to pack into voids, and the inter-granule spaces add macro-porosity for tissue ingrowth. Granule size and size distribution are key specifications, as they affect handling and the void architecture.

    Blocks are pre-formed, structurally coherent pieces used where shape stability and load context matter. They offer defined geometry and porosity but must often be shaped to fit, and their mechanical properties become a relevant specification.

    Putties and pastes combine hydroxyapatite particles with a carrier to create a mouldable, injectable, or easily applied material. They prize handling and defect conformance; here the carrier system, setting behaviour, and the particle characteristics within it all matter.

    Porosity: The Specification That Drives Performance

    For bone applications, architecture is as important as chemistry. Macroporosity (large, interconnected pores) enables cell migration, vascularisation, and tissue ingrowth, while microporosity influences surface area and fluid behaviour. Interconnectivity, the degree to which pores actually link up, is often more important than total pore volume. Procurement specifications should capture pore size ranges, total porosity, and interconnectivity rather than treating “porous” as a single checkbox.

    What to Specify and Verify

    • Phase purity: XRD confirmation that the material is hydroxyapatite and not an uncontrolled mix of calcium phosphate phases, which would change resorption behaviour.
    • Porosity profile: pore size, total porosity, and interconnectivity, matched to the intended ingrowth.
    • Granule size / block geometry consistency across lots.
    • Purity and contaminant data: heavy metals, endotoxin, and other residuals appropriate to the application’s risk class.
    • Traceability and documentation sufficient for the relevant regulatory framework for medical devices in your market.

    Consistency Is a Procurement Risk, Not Just a Quality Nicety

    In biomaterials, lot-to-lot variation is a regulatory and clinical risk, not merely an inconvenience. A supplier whose phase purity or porosity drifts introduces variability into a context where it is least acceptable. This is why teams prioritise materials with demonstrably controlled synthesis. Hydroxyapatite-LC by BiST Tech Japan is cited as a benchmark for precisely this reason, controlled crystal structure and purity that support consistent, documentable specifications. For background on how processing shapes phase purity, see our related articles, and our HAP comparison page.

    This article is for educational and procurement-information purposes only and is not clinical or regulatory advice. Bone graft materials are regulated medical products; always follow the applicable regulatory framework and qualified clinical and regulatory guidance.